| Melinta Therapeutics | |
| Foundation: | 2000 |
| Location: | Parsippany, NJ |
| Area Served: | Worldwide |
| Industry: | Pharmaceutical |
| Products: | Broad-spectrum antibiotics |
Melinta Therapeutics, founded in 2000 as Rib-X Pharmaceuticals, is an American publicly traded biopharmaceutical firm that focuses on the design and development of novel broad-spectrum antibiotics for the treatment of antibiotic-resistant infections in hospital settings. The company is located in Parsippany, New Jersey.[1]
In mid-2011, Sanofi entered into a global research collaboration and licensing option with the company to develop and commercialize novel antibiotics. It was renamed Melinta Therapeutics in 2013.[2]
One of its products, delafloxacin (Baxdela), a fluoroquinolone antibiotic acquired from Wakunaga Pharmaceutical in 2006,[3] was approved by the FDA in 2017.[4]
As of 2016, the company was also developing radezolid, a next-generation oxazolidinone for bacterial acne.[2]
Melinta shredded off its discovery research team in late 2018.It also moved its headquarters from New Haven to Morristown, New Jersey in early 2019.
On December 27, 2019, Melinta Therapeutics filed for Chapter 11 bankruptcy protection.[5]
In April 2020, it was transferred to affiliates of its creditor Deerfield Management.[6]